How much of Cassava Sciences’ revenue comes from haram?

Cassava Sciences currently does not generate revenue.

Cassava Sciences is a clinical-stage biotechnology company focused on developing drugs and diagnostics against neurodegenerative diseases such as Alzheimer’s. 

Its lead therapeutic candidate, Simufilam, has passed the phase 2b clinical trial. 

In addition, Cassava is developing an investigational diagnostic candidate, SavaDx, a blood-based biomarker to detect Alzheimer’s disease. 

Practical Islamic Finance concludes:

None of Cassava Sciences’ revenue comes from anything inherently haram.

What are Cassava Sciences’ Environmental, Social, and Governance (ESG) Impact?

Environment

No notable environmental highlights.

Social

Alzheimer’s disease is the sixth leading cause of death in the United States.  

According to the National Institute of Aging, more than 6 million Americans aged 65 or older may have dementia caused by Alzheimer’s.

Cassava Sciences has the potential to positively impact the lives of patients living with the disease.

Governance

No notable governance highlights.

Practical Islamic Finance concludes: 

Cassava Sciences has a net positive ESG impact. 

Comfort Rating 

From Cassava Sciences’ business, financial, and ESG reviews, Practical Islamic Finance rates Cassava Sciences stock as: 

Comfortable to invest in from a halal perspective.

Sources

Cassava Sciences 2020 Annual Report 

Cassava Sciences 2021 Q3 10Q